NCT02833415View on ClinicalTrials.gov

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

November 30, 2018

Conditions
Obesity, Visceral
Interventions
DRUG

[U-13C3] glycerol

Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).

DRUG

Empagliflozin

Active drug

DRUG

Placebo (for Empagliflozin)

Placebo tablet manufactured to mimic EMPA 10 mg tablet.

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT02833415 - Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging | Biotech Hunter | Biotech Hunter